Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes (Q45137094)

9 December 2017

title

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes (English)

1 reference

9 December 2017

1 reference

1 reference

Alex Sparreboom

1 reference

9 December 2017

Jaap Verweij

1 reference

9 December 2017

Trinet Rietveld

1 reference

9 December 2017

Ron H J Mathijssen

1 reference

9 December 2017

Floris A de Jong

1 reference

9 December 2017

Ron H N van Schaik

1 reference

9 December 2017

Erin R Lepper

1 reference

9 December 2017

Lena E Friberg

1 reference

9 December 2017

Peter de Bruijn

1 reference

9 December 2017

Wilfried J Graveland

1 reference

9 December 2017

William D Figg

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Journal of the National Cancer Institute

9 December 2017

published in

1 reference

9 December 2017

1 reference

9 December 2017

1 reference

9 December 2017

page(s)

1585-1592

1 reference

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgki n's Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Herbal remedies in the United States: potential adverse interactions with anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Cytochrome P450 gene polymorphism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Use of probe drugs as predictors of drug metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

The erythromycin breath test for the prediction of drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Modulation of irinotecan metabolism by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Effects of St. John's wort on irinotecan metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Genetic variability in CYP3A5 and its possible consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH298

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH298

1 reference

9 December 2017

1 reference